# Vivos Targets $3.8 Million Revenue Lift

> Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract talks by early 2027.
- Title: Vivos Targets $3.8 Million Revenue Lift · TokenPost | Shortify
- Summary: Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract talks by early 2027.
- Keywords: vivos therapeutics, payer contract, revenue lift, nasdaq, operating cash flow, financial risk, crypto, TokenPost
- URL: https://shortify.news/TokenPost/vivos-targets-38-million-revenue-lift
- Source: TokenPost — https://tokenpost.com/news/business/59722
- Published: 2026-11-17T18:10:59+00:00
- Read time: 1 min
- Topics: vivos therapeutics, payer contract, revenue lift, nasdaq, operating cash flow, financial risk, crypto, finance
## Vivos Therapeutics Revenue Target
Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract renegotiations to achieve positive operating cash flow by early 2027.
## Financial Risks
Management reported $200,000 in cash and warned of substantial doubt about Vivos’ ability to continue as a going concern.
## Nasdaq Listing Risk
Vivos remains out of compliance with Nasdaq’s $1 minimum bid-price requirement, risking delisting if the closing bid stays at or below $0.10 for 10 straight business days.
## Key takeaway

Vivos Therapeutics targets $3.8 million in additional annual revenue from payer contract renegotiations to achieve positive operating cash flow by early 2027.

---

Summary: Shortify — https://shortify.news/TokenPost/vivos-targets-38-million-revenue-lift
Reporting: TokenPost — https://tokenpost.com/news/business/59722

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.